Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/121"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of administration: not mentioned
study duration: not mentioned
population: not mentioned
tested for known CYP450 polymorphisms?
NO
ages: not mentioned
Quote:
In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of PRISTIQ (400 mg single dose) by about 43% and Cmax by about 8%. Concomitant use of PRISTIQ with potent inhibitors of CYP3A4 may result in higher concentrations of PRISTIQ."
|
| dc:creator | |
| dc:date |
"02/16/2012 21:52:08"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ ketoconazole_increases_auc_desvenlafaxine, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1512 }